Physician profile
Michael M Bahrami
NPI 1568470417
$1,850.13
in general payments reported to CMS, 2019-2025
19 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2020: $551 · 2021: $148 · 2022: $149 · 2023: $90.86 · 2024: $55.27 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $597.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $500.00 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $325.13 | 2019-2025 | Jardiance |
| Medtronic, INC. | $247.66 | 2023-2025 | Aurora Ev-Icd Mri Surescan, Mycarelink, Closurefast |
| Medtronic Vascular, INC. | $160.43 | 2019 | |
| Biotronik INC. | $143.94 | 2019 | |
| Novo Nordisk INC | $98.72 | 2023-2025 | Wegovy, Rybelsus |
| Pfizer INC. | $94.44 | 2019-2021 | |
| Cook Medical LLC | $93.29 | 2022 | |
| Janssen Pharmaceuticals, INC | $57.00 | 2019-2021 | |
| Vital Connect, INC | $27.27 | 2025 | Vitalpatch Rtm |
| Intra-Sana Laboratories | $25.82 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Forte Bio-Pharma LLC | $24.79 | 2025 | Prolate, Tanlor, Nalocet |
| Lilly USA, LLC | $21.00 | 2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $15.40 | 2023 | Brilinta |
| E.R. Squibb & Sons, L.L.C. | $15.24 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bahrami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.